GALA/PEG2000-MENDssPalmE / anti-CD31 siRNA
Sequence: WEAALAEALAEALAEHLAEALAEALEALAA
| Experiment Id | EXP002473 |
|---|---|
| Paper | PEGylation of the GALA Peptide Enhances the Lung-Targeting Activity of Nanocarriers That Contain Enc |
| Peptide | GALA/PEG2000-MENDssPalmE / anti-CD31 siRNA |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | GALA/PEG2000 post-modification optimized at 2 mol% on MENDssPalmE |
| Rna Concentration | 0.01–0.5 mg/kg for dose response; 0.5 mg/kg in optimization experiment |
| Mixing Ratio | siRNA encapsulated in MENDssPalmE; GALA/PEG2000 surface ligand density varied 0.5–2 mol% |
| Formulation Format | lipid nanoparticle / multifunctional envelope-type nano device (MEND) |
| Formulation Components | ssPalmE and cholesterol 7:3; DMG-PEG2000 3 mol%; GALA/PEG2000 post-modification; anti-CD31 siRNA encapsulated |
| Size Nm | 169.00 |
| Zeta Mv | -10.20 |
| Model Scope | in_vivo |
| Model Type | in vivo lung endothelium gene silencing |
| Cell Lines Or Primary Cells | |
| Animal Model | C57BL/6N male mice; lung endothelial CD31 knockdown assay |
| Administration Route | intravenous tail-vein injection |
| Output Type | in vivo target-gene knockdown |
| Output Value | CD31 mRNA knockdown in lung; ED50 approximately 0.21 mg/kg for 2 mol% GALA/PEG2000-MENDssPalmE; marginal nonspecific liver silencing at optimized condition |
| Output Units | |
| Output Notes | GALA/PEG2000-MENDssPalmE enhanced lung-endothelium CD31 silencing compared with unmodified MENDssPalmE; sequence-dependent knockdown confirmed by scramble control; no separate in vitro RNA-function row included because in vitro GALA/PEG liposome uptake assays used no siRNA cargo. |
| Toxicity Notes | No body-weight changes reported for CD31 siRNA-encapsulating GALA/PEG2000-MENDssPalmE; authors note further translational safety study is needed |
| Curation Notes |